Trevi Therapeutics

TRVINASDAQ
$2.85
00.00%
Pre-Market: 4:01 PM EDT
15 minutes delayed
Trevi Therapeutics (TRVI) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$10.00
Lowest Price Target1
$6.00
Consensus Price Target1
$7.57

want to know what
the Bulls & Bears Say?

Trevi Therapeutics (NASDAQ:TRVI) Stock, Analyst Ratings, Price Targets, Forecasts

Trevi Therapeutics Inc has a consensus price target of $7.57 based on the ratings of 7 analysts. The high is $10 issued by Aegis Capital on March 29, 2022. The low is $6 issued by B. Riley Securities on April 12, 2023. The 3 most-recent analyst ratings were released by Rodman & Renshaw, Needham, and Needham on June 13, 2024, May 8, 2024, and April 9, 2024, respectively. With an average price target of $7.67 between Rodman & Renshaw, Needham, and Needham, there's an implied 169.01% upside for Trevi Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Mar
0
0
0
0
Apr
0
0
0
0
May
0
0
0
0
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Rodman & Renshaw
Needham
Oppenheimer
B. Riley Securities
JonesTrading

1calculated from analyst ratings

Analyst Ratings for Trevi Therapeutics

Buy NowGet Alert
06/13/2024Buy Now145.61%Rodman & Renshaw
Brandon Folkes
 → $7Initiates → BuyGet Alert
05/08/2024Buy Now180.7%Needham
Serge Belanger
 → $8ReiteratesBuy → BuyGet Alert
04/09/2024Buy Now180.7%Needham
Serge Belanger
 → $8ReiteratesBuy → BuyGet Alert
03/21/2024Buy Now180.7%Needham
Serge Belanger
 → $8ReiteratesBuy → BuyGet Alert
03/21/2024Buy Now215.79%Oppenheimer
Leland Gershell
$9 → $9MaintainsOutperformGet Alert
08/11/2023Buy Now180.7%Needham
Serge Belanger
 → $8ReiteratesBuy → BuyGet Alert
05/12/2023Buy Now180.7%Needham
Serge Belanger
 → $8ReiteratesBuy → BuyGet Alert
04/18/2023Buy Now180.7%Needham
Serge Belanger
 → $8Reiterates → BuyGet Alert
04/12/2023Buy Now110.53%B. Riley Securities
Mayank Mamtani
 → $6Initiates → BuyGet Alert
03/17/2023Buy Now180.7%Needham
Serge Belanger
 → $8Reiterates → BuyGet Alert
03/14/2023Buy Now145.61%JonesTrading
Sean Kim
 → $7Initiates → BuyGet Alert
11/22/2022Buy Now110.53%SVB Leerink
Thomas Smith
 → $6Initiates → OutperformGet Alert
11/11/2022Buy Now180.7%Needham
Serge Belanger
$10 → $8MaintainsBuyGet Alert
06/30/2022Buy Now250.88%Needham
Serge Belanger
$8 → $10MaintainsBuyGet Alert
05/25/2022Buy Now250.88%Oppenheimer
Leland Gershell
 → $10Initiates → OutperformGet Alert
03/29/2022Buy Now250.88%Aegis Capital
Nathan Weinstein
 → $10Initiates → BuyGet Alert
11/11/2021Buy Now180.7%Needham
Serge Belanger
—MaintainsBuyGet Alert
08/13/2021Buy Now250.88%Needham
Serge Belanger
—MaintainsBuyGet Alert

FAQ

Q

What is the target price for Trevi Therapeutics (TRVI) stock?

A

The latest price target for Trevi Therapeutics (NASDAQ:TRVI) was reported by Rodman & Renshaw on June 13, 2024. The analyst firm set a price target for $7.00 expecting TRVI to rise to within 12 months (a possible 145.61% upside). 6 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Trevi Therapeutics (TRVI)?

A

The latest analyst rating for Trevi Therapeutics (NASDAQ:TRVI) was provided by Rodman & Renshaw, and Trevi Therapeutics initiated their buy rating.

Q

When was the last upgrade for Trevi Therapeutics (TRVI)?

A

There is no last upgrade for Trevi Therapeutics

Q

When was the last downgrade for Trevi Therapeutics (TRVI)?

A

There is no last downgrade for Trevi Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Trevi Therapeutics (TRVI)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Trevi Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Trevi Therapeutics was filed on June 13, 2024 so you should expect the next rating to be made available sometime around June 13, 2025.

Q

Is the Analyst Rating Trevi Therapeutics (TRVI) correct?

A

While ratings are subjective and will change, the latest Trevi Therapeutics (TRVI) rating was a initiated with a price target of $0.00 to $7.00. The current price Trevi Therapeutics (TRVI) is trading at is $2.85, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch